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ABSTRACT
Objective To analyse the available evidence on
cardiovascular safety of non-steroidal anti-inflammatory
drugs.
Design Network meta-analysis.
Data sources Bibliographic databases, conference
proceedings, study registers, the Food and Drug
Administration website, reference lists of relevant
articles, and reports citing relevant articles through the
Science Citation Index (last update July 2009).
Manufacturers of celecoxib and lumiracoxib provided
additional data.
Study selection All large scale randomised controlled
trials comparing any non-steroidal anti-inflammatory drug
with other non-steroidal anti-inflammatory drugs or
placebo. Two investigators independently assessed
eligibility.
Data extraction The primary outcome was myocardial
infarction. Secondary outcomes included stroke, death
from cardiovascular disease, and death from any cause.
Two investigators independently extracted data.
Data synthesis31 trials in 116429 patientswithmore than
115000 patient years of follow-up were included. Patients
were allocated to naproxen, ibuprofen, diclofenac,
celecoxib, etoricoxib, rofecoxib, lumiracoxib, or placebo.
Compared with placebo, rofecoxib was associated with the
highest risk of myocardial infarction (rate ratio 2.12, 95%
credibility interval 1.26 to 3.56), followed by lumiracoxib
(2.00, 0.71 to 6.21). Ibuprofen was associated with the
highest risk of stroke (3.36, 1.00 to 11.6), followed by
diclofenac (2.86, 1.09 to 8.36). Etoricoxib (4.07, 1.23 to
15.7) and diclofenac (3.98, 1.48 to 12.7) were associated
with the highest risk of cardiovascular death.
ConclusionsAlthoughuncertainty remains, little evidence
exists to suggest that any of the investigated drugs are
safe in cardiovascular terms. Naproxen seemed least
harmful. Cardiovascular risk needs to be taken into
account when prescribing any non-steroidal anti-
inflammatory drug.
INTRODUCTION
Non-steroidal anti-inflammatory drugs (NSAIDs) have
been the cornerstone of pain management in patients
with osteoarthritis and other painful conditions. In the
United States an estimated 5%of all visits to a doctor are
related to prescriptions of non-steroidal anti-inflamma-
tory drugs and they are among the most commonly
used drugs.12 In 2004, rofecoxib, marketed as a cyclo-
oxygenase-2 (COX 2) selective inhibitor, was with-
drawn from themarket after the results of a randomised
placebo controlled trial3 showed an increased risk of
cardiovascular events associated with the drug. This
finding was confirmed in other trials and a cumulative
meta-analysis.4 Since then debate has surrounded the
cardiovascular safety of cyclo-oxygenase-2 selective
inhibitors, followed by similar concerns about tradi-
tional non-steroidal anti-inflammatory drugs.5 More
recently, the US Food and Drug Administration
decided against the approval of etoricoxib because of
its inadequate risk-benefit profile.6
These debates and the patchwork of evidence result-
ing from multiple trials and cohort studies have
unsettled practising clinicians.7 Several standard
meta-analyses were unable to resolve the debate
because they failed to integrate all available rando-
mised evidence in one analysis.Networkmeta-analysis
allows a unified, coherent analysis of all randomised
controlled trials that compare non-steroidal anti-
inflammatory drugs head to head or with placebo
while fully respecting randomisation.8 9 We analysed
the cardiovascular safety of non-steroidal anti-inflam-
matory drugs by integrating all available direct and
indirect evidence in network meta-analyses.
METHODS
We considered large scale randomised controlled trials
comparing any non-steroidal anti-inflammatory drug
with other non-steroidal anti-inflammatory drugs, para-
cetamol (acetaminophen), or placebo for any medical
condition. To be included, trials required at least two
arms with at least 100 patient years of follow-up. In the
case of trials with several arms, we included only arms
withat least 100patientyearsof follow-up.Weexcluded
trials in patients with cancer. For an intervention to be
included in our analyses, at least 10 patients allocated to
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the intervention had to have had a myocardial infarc-
tion in all eligible trials combined.
Trial identification and data collection
We searched bibliographic databases, relevant confer-
ence proceedings, study registers, and the FDA web-
site, manually searched reference lists of relevant
articles, and retrieved reports citing relevant articles
through the Science Citation Index (see web extra
appendix 1). The search was last updated in July
2009. Two investigators independently assessed trials
for eligibility and extracted data. If a trial was covered
in more than one report we used a hierarchy of data
sources: reports to the FDA, peer reviewed articles,
reports from the web based repository for results of
clinical studies www.clinicalstudyresults.org, pub-
lished abstracts, and other sources, such as trial web-
sites. Finally, we contacted all authors of primary trial
reports and manufacturers of relevant non-steroidal
anti-inflammatory drugs (Pfizer, Merck, Novartis) for
missing outcome data.One independent investigator10
and two manufacturers (Pfizer and Novartis) provided
additional information.
Outcome measures
The prespecified primary outcome was fatal or non-
fatal myocardial infarction. Secondary outcomes
were haemorrhagic or ischaemic fatal or non-fatal
stroke; cardiovascular death, defined as any death
due to cardiovascular causes (for example, myocardial
infarction, low output failure, fatal arrhythmia, pul-
monary embolism, stroke), and death of unknown
cause; death from any cause; and the Antiplatelet Tri-
alists’Collaboration composite outcome11 of non-fatal
myocardial infarction, non-fatal stroke, or cardio-
vascular death.
Statistical analysis
Whenever possible we used results from intention to
treat analysis of the longest follow-up available. We
excluded comparisons with zero events in both groups
from the relevant analysis since such comparisons pro-
vide no information on themagnitude of the treatment
effect.12 We used a Bayesian random effects model,
which fully preserves randomised treatment compari-
sons within trials.9 13 14 Analyses were done using Mar-
kov chain Monte Carlo methods with minimally
informative prior distributions. As measures of treat-
ment effects, we calculated rate ratios based on patient
years. We estimated rate ratios from the median of the
posterior distribution as well as corresponding 95%
credibility intervals. In the presence of minimally
informative priors, credibility intervals can be inter-
preted like conventional confidence intervals. Rate
ratios below 1 indicate a detrimental effect of the con-
trol intervention throughout. Finally, we calculated
confidence levels, defined as the posterior probability
that an increase in risk is smaller than a specified
threshold.15 Confidence levels take into account both
the magnitude of the pooled rate ratio and the corre-
sponding uncertainty. Precise estimates are more
informative and result in sharp increases in the confi-
dence that the rate ratio of a drug does not exceed a
specified threshold. When the specified threshold of
the rate ratio increases, imprecise estimates that are
based on low numbers of events are uninformative
and lead to slow increases in confidence and relevant
uncertainty even for large rate ratios. We prespecified
a rate ratio of 1.3 as the primary threshold, which was
used as non-inferiority margin in the Multinational
Etoricoxib and Diclofenac Arthritis Long-term
(MEDAL) programme.16 We used linear regression
to test for each outcomewhether therewas any associa-
tion with cyclo-oxygenase-2 selectivity (data only
shown in web extra appendix 2).
We assessed the goodness of fit of the model to the
data by calculating the residual deviance,9 the hetero-
geneity of treatment effects estimated from themedian
between trial variance τ2 observed in the posterior dis-
tribution, and the consistency of the network deter-
mined by use of inconsistency factors,17 defined as
the difference in log rate ratios derived from direct
and indirect comparisons. To check the robustness of
our analyses, we calculated Bayesian random effects
meta-analyses for all available direct comparisons
and carried out several sensitivity analyses, including
a restriction to trials in patients with musculoskeletal
conditions (data shown in web extra appendix 2). For
all analyses we used Stata release 10, and WinBUGS
version 1.4 (MRCBiostatistics Unit, Cambridge, UK).
Web extra appendix 1 provides further details of the
methods used.
RESULTS
Thirty one randomised controlled trials evaluating
seven different non-steroidal anti-inflammatory drugs
were included in the analyses (table 1, fig 1). Celecoxib
Placebo
Celecoxib
Lumiracoxib Naproxen
Rofecoxib
DiclofenacIbuprofen
Etoricoxib
3 (3782
patient
years)
3 (5319
patient
years)
2 (1412
patient
years)
3 (3457
patient
years)
3 (50 986
patient
years)
2 (643
patient
years)
1 (7504
patient
years)
3 (940
patient
years)
1 (2307
patient
years)
4 (5539
patient
years)
6 (12 799
patient
years)
2 (8705
patient
years)
6 (19 710
patient
years)
Fig 1 | Network of comparisons included in analyses. Solid
lines represent direct comparisons within randomised
controlled trials. Numbers denote trials comparing
corresponding interventions, with overall number of patient
years of follow-up in brackets
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was investigated most (15 trials) and compared with
five different interventions. Ibuprofen was evaluated
least (two trials) and comparedwith two different inter-
ventions, whereas etoricoxib was evaluated in three
trials but compared with only one intervention. Etori-
coxib and diclofenac had the largest number of patient
years of follow-up (26 025 and 27 819 overall, respec-
tively), whereas ibuprofen had the lowest number of
patient years of follow-up (4832 overall). In total,
116 429 patients with 117 218 patient years of follow-
up were covered in the analysis of the primary out-
come (table 2). Themethodological quality of included
trials was generally high with all but two having ade-
quate concealment of allocation, all having adequate
blinding of patients and investigators, 16 having inde-
pendent event adjudication, and 13 including all ran-
domised patients in the analysis (table 1).
Myocardial infarction
Twenty nine trials with 554 accumulated events con-
tributed to the analysis of myocardial infarction
(table 2). For three of the preparations (naproxen,
diclofenac, and etoricoxib) evidence was lacking for
an increased risk of myocardial infarction compared
with placebo (fig 2). All other drugs seemed to be asso-
ciated with an increased risk compared with placebo.
Estimated rate ratios were greater than 1.3 for ibupro-
fen (1.61, 95% credibility interval 0.50 to 5.77), cele-
coxib (1.35, 0.71 to 2.72), rofecoxib (2.12, 1.26 to
3.56), and lumiracoxib (2.00, 0.71 to 6.21).
Stroke
Twenty six trials with 377 accumulated events contrib-
uted to the analysis of stroke (table 2). All drugs
seemed to be associated with an increased risk com-
pared with placebo (fig 2). Estimated rate ratios were
greater than 1.3 for naproxen (1.76, 0.91 to 3.33), ibu-
profen (3.36, 1.00 to 11.60), diclofenac (2.86, 1.09 to
8.36), etoricoxib (2.67, 0.82 to 8.72), and lumiracoxib
(2.81, 1.05 to 7.48).
Cardiovascular death
Twenty six trials with 312 accumulated events contrib-
uted to the analysis of cardiovascular death, accounting
for 46% of all deaths (table 2). All drugs except
naproxen showed some evidence for an increased
risk of cardiovascular death compared with placebo
(fig 2). The estimated rate ratios for cardiovascular
death were greater than 1.3 for ibuprofen (2.39, 0.69
to 8.64), diclofenac (3.98, 1.48 to 12.70), celecoxib
(2.07, 0.98 to 4.55), etoricoxib (4.07, 1.23 to 15.70),
rofecoxib (1.58, 0.88 to 2.84), and lumiracoxib (1.89,
0.64 to 7.09).
Death from any cause
Twenty eight trials with 676 accumulated events con-
tributed to the analysis on overall mortality (table 2).
All the drugs seemed to be associated with increased
risks of death from any cause compared with placebo
(fig 2). The estimated rate ratios were greater than 1.3
for ibuprofen (1.77, 0.73 to 4.30), diclofenac (2.31, 1.00
to 4.95), celecoxib (1.50, 0.96 to 2.54), etoricoxib (2.29,
0.94 to 5.71), rofecoxib (1.56, 1.04 to 2.23), and lumi-
racoxib (1.75, 0.78 to 4.17).
Myocardial infarction
  Naproxen
  Ibuprofen
  Diclofenac
  Celecoxib
  Etoricoxib
  Rofecoxib
  Lumiracoxib
Stroke
  Naproxen
  Ibuprofen
  Diclofenac
  Celecoxib
  Etoricoxib
  Rofecoxib
  Lumiracoxib
Cardiovascular death
  Naproxen
  Ibuprofen
  Diclofenac
  Celecoxib
  Etoricoxib
  Rofecoxib
  Lumiracoxib
Death from any cause
  Naproxen
  Ibuprofen
  Diclofenac
  Celecoxib
  Etoricoxib
  Rofecoxib
  Lumiracoxib
APTC composite outcome
  Naproxen
  Ibuprofen
  Diclofenac
  Celecoxib
  Etoricoxib
  Rofecoxib
  Lumiracoxib
0.82 (0.37 to 1.67)
1.61 (0.50 to 5.77)
0.82 (0.29 to 2.20)
1.35 (0.71 to 2.72)
0.75 (0.23 to 2.39)
2.12 (1.26 to 3.56)
2.00 (0.71 to 6.21)
1.76 (0.91 to 3.33)
3.36 (1.00 to 11.60)
2.86 (1.09 to 8.36)
1.12 (0.60 to 2.06)
2.67 (0.82 to 8.72)
1.07 (0.60 to 1.82)
2.81 (1.05 to 7.48)
0.98 (0.41 to 2.37)
2.39 (0.69 to 8.64)
3.98 (1.48 to 12.70)
2.07 (0.98 to 4.55)
4.07 (1.23 to 15.70)
1.58 (0.88 to 2.84)
1.89 (0.64 to 7.09)
1.23 (0.71 to 2.12)
1.77 (0.73 to 4.30)
2.31 (1.00 to 4.95)
1.50 (0.96 to 2.54)
2.29 (0.94 to 5.71)
1.56 (1.04 to 2.23)
1.75 (0.78 to 4.17)
1.22 (0.78 to 1.93)
2.26 (1.11 to 4.89)
1.60 (0.85 to 2.99)
1.43 (0.94 to 2.16)
1.53 (0.74 to 3.17)
1.44 (1.00 to 1.99)
2.04 (1.13 to 4.24)
0.2 0.5 1 2 5
Favours
NSAID
Favours
placebo
Rate ratio
(95% credibility
interval)
Rate ratio
(95% credibility
interval)
Fig 2 | Estimates of rate ratios for non-steroidal anti-
inflammatory drugs compared with placebo. NSAID=non-
steroidal anti-inflammatory drug; APTC=Antiplatelet Trialists’
Collaboration
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Table 1 | Characteristics of included trials
Trial Interventions Population
No of
patients*
Follow-up
(weeks)
Low dose
aspirin
allowed
Concealed
allocation† Blinding‡
Events
adjudica-
ted§
Intention to
treat Source
ADAPT Placebo v naproxen (440 mg/d) v
celecoxib (400 mg/d)
At risk for Alzheimer
disease
2528 198 Yes Yes Yes Yes Yes Journal article,w1 trial websitew2
Aisen 2003 Placebo v naproxen (440 mg/d) v
rofecoxib (25 mg/d)
Alzheimer disease 351 60 Yes Yes Yes No Yes Journal article,w3 personal
communicationw4
Geusens 2004 Placebo v naproxen (1000 mg/d)
v lumiracoxib (200, 400 mg/d)
Rheumatoid
arthritis
1124 26 Yes Yes Yes No Yes Journal article,w5 personal
communicationw6 w7
APC Placebo v celecoxib (400,
800 mg/d)
Adenomatous
polyps (colon)
2035 160 Yes Yes Yes Yes Yes Journal article,w8 study registerw9
GAIT Placebo v celecoxib (200 mg/d) Osteoarthritis 631 24 No Yes Yes No Yes Journal articlew10
IQ5-97-02-001 Placebo v celecoxib (400 mg/d) At risk for Alzheimer
disease
425 52 Yes Yes Yes No No FDA reports,w11 study register,w12
personal communicationw13 w14
PreSAP Placebo v celecoxib (400 mg/d) Adenomatous
polyps (colon)
1561 159 Yes Yes Yes Yes Yes Journal article,w15 personal
communicationw13 w14
Lehmann2005 Placebo v celecoxib (200 mg/d) v
lumiracoxib (100 mg/d)
Osteoarthritis 1684 13 Yes Yes Yes Yes Yes Journal article,w16 personal
communicationw6 w7
APPROVe Placebo v rofecoxib (25 mg/d) Adenomatous
polyps (colon)
2586 229 Yes Unclear Yes Yes Yes Journal articlew17
Reines 2004 Placebo v rofecoxib (25 mg/d) Alzheimer disease 692 65 Unclear Yes Yes Yes Yes FDA reportsw18
Thal 2005 Placebo v rofecoxib (25 mg/d) At risk for Alzheimer
disease
1457 210 Yes Yes Yes Yes Yes Journal articlew19
VICTOR Placebo v rofecoxib (25 mg/d) Adjuvant (colon
cancer)
2327 235 Yes Yes Yes Yes No FDA reports,w18 journal article,w20
study register,w21 trial websitew22
ViP Placebo v rofecoxib (25 mg/d) At risk for prostate
cancer
4741 75 Yes Yes Yes Yes Yes Study registerw23
A3191152 Naproxen (1000 mg/d) v
celecoxib (200 mg/d)
Osteoarthritis 589 26 Yes Yes Yes No No Study registerw24
SUCCESS-1
(USA/Canada)
Naproxen (1000 mg/d) v
celecoxib (200, 400 mg/d)
Osteoarthritis 2736 12 Yes Yes Yes No No Journal article,w25 study
register,w26 personal
communicationw13 w14
ADVANTAGE Naproxen (1000 mg/d) v
rofecoxib (25 mg/d)
Osteoarthritis 5557 14 Yes Unclear Yes Yes No FDA reports,w18 w27 journal
articlew28 w29
VIGOR Naproxen (1000 mg/d) v
rofecoxib (50 mg/d)
Rheumatoid
arthritis
8076 54 No Yes Yes Yes Yes FDA reports,w18 w27 w30 journal
articlew31
TARGET (0117) Naproxen (1000 mg/d) v
lumiracoxib (400 mg/d)
Osteoarthritis 9511 56 Yes Yes Yes Yes No FDA reports,w32 journal article,w33
personal communicationw6 w7
CLASS (N49-
98-02-035)
Ibuprofen (2400 mg/d) v
celecoxib (800 mg/d)
Osteoarthritis and
rheumatoidarthritis
3975 65 Yes Yes Yes No No FDA reports,w11 w34 w35 personal
communicationw13 w14
TARGET (2332) Ibuprofen (2400 mg/d) v
lumiracoxib (400 mg/d)
Osteoarthritis 8814 56 Yes Yes Yes Yes No FDA reports,w23 journal article,w33
personal communicationw6 w7
CAESAR Diclofenac (100 mg/d) v
celecoxib (200 mg/d)
Osteoarthritis 916 52 Yes Yes Yes No No FDA reports,w11 study register,w36
conference abstract,w37 personal
communicationw13 w14
CLASS (N49-
98-02-102)
Diclofenac (150 mg/d) v
celecoxib (800 mg/d)
Osteoarthritis and
rheumatoidarthritis
3993 52 Yes Yes Yes No No FDA reports,w11 w34 w35 personal
communicationw13 w14
Emery 1999 Diclofenac (150 mg/d) v
celecoxib (400 mg/d)
Rheumatoid
arthritis
655 24 No Yes Yes No No Journal article,w38 personal
communicationw13 w14
SUCCESS-1
(World)
Diclofenac (100 mg/d) v
celecoxib (200, 400 mg/d)
Osteoarthritis 10458 12 Yes Yes Yes No No Journal article,w25 study
register,w26 personal
communicationw13 w14
EDGE Diclofenac (150 mg/d) v
etoricoxib (90 mg/d)
Osteoarthritis 7111 73 Yes Yes Yes Yes No FDA reports,w39 journal articlew40
EDGE II Diclofenac (150 mg/d) v
etoricoxib (90 mg/d)
Rheumatoid
arthritis
4086 150 Yes Yes Yes Yes No Journal articlew41
MEDAL Diclofenac (150 mg/d) v
etoricoxib (60, 90 mg/d)
Osteoarthritis and
rheumatoidarthritis
23498 176 Yes Yes Yes Yes No Journal articlew42
Cannon 2000 Diclofenac(150mg/d)v rofecoxib
(12.5, 25 mg/d)
Osteoarthritis 784 52 No Yes Yes No No FDA reports,w43 w44 journal
articlew45
Saag 2000 Diclofenac(150mg/d)v rofecoxib
(12.5, 25 mg/d)
Osteoarthritis 693 54 No Yes Yes No No FDA reports,w43 w44 journal
articlew46
Fleischmann
2003**
Celecoxib (200 mg/d) v
lumiracoxib (200, 400 mg/d)
Osteoarthritis 1376 13 Yes Yes Yes No No Journal article,w47 personal
communicationw6 w7
Tannenbaum
2004**
Celecoxib (200 mg/d) v
lumiracoxib (200, 400 mg/d)
Osteoarthritis 1459 13 Yes Yes Yes No Yes Journal article,w48 personal
communicationw6 w7
FDA=US Food and Drug Administration. See web extra appendix 3 for full names of trials and references to sources.
*Number of randomised patients of included trial arms.
†Yes if investigators responsible for patient selection were unable to suspect before allocation which treatment was next in line (central randomisation, sequentially numbered, sealed,
opaque assignment envelopes, coded drug packs).
‡Yes if drugs looked similar (for example, matching placebo) or double dummy was used.
§Relates to myocardial infarctions only. See web extra appendix 2 for more detailed description of external adjudication of events in individual trials.
¶Yes if all randomised patients were included in analysis.
**Placebo arm excluded (<100 patient years of follow-up).
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Table 2 | Number of events by randomised intervention for each outcome
Trial Intervention
Patient
years*
Myocardial
infarction† Stroke†
Cardiovascular
death Death‡
APTC composite
outcome
ADAPT Placebo 1982 13 7 3 12 22
ADAPT Naproxen 1332 13 10 3 11 23
ADAPT Celecoxib 1346 8 7 4 9 17
Aisen 2003 Placebo 115 1 1 1 1 2
Aisen 2003 Naproxen 124 0 5 1 1 6
Aisen 2003 Rofecoxib 126 3 4 2 2 7
Geusens 2004 Placebo 111 0 1 0 0 1
Geusens 2004 Naproxen 118 0 0 0 0 0
Geusens 2004 Lumiracoxib 234 2 3 2 2 6
APC Placebo 1558 3 3 1 6 7
APC Celecoxib 3124 18 8 11 18 37
GAIT Placebo 140 NA NA 0 0 NA
GAIT Celecoxib 146 NA NA 0 0 NA
IQ5-97-02-001 Placebo 120 0 3 2 4 3
IQ5-97-02-001 Celecoxib 285 2 7 8 13 12
PreSAP Placebo 1570 4 7 4 7 12
PreSAP Celecoxib 2331 9 9 4 11 21
Lehmann 2005 Placebo 98 1 0 0 0 1
Lehmann 2005 Celecoxib 99 0 0 0 0 0
Lehmann 2005 Lumiracoxib 200 0 1 1 1 2
APPROVe Placebo 5711 18 9 13 28 34
APPROVe Rofecoxib 5658 34 19 16 36 59
Reines 2004 Placebo 293 4 5 3 8 12
Reines 2004 Rofecoxib 273 2 1 4 14 4
Thal 2005 Placebo 1820 13 15 3 20 28
Thal 2005 Rofecoxib 1599 22 7 13 41 33
VICTOR Placebo 986 1 3 3 NA 6
VICTOR Rofecoxib 928 6 3 4 NA 9
ViP Placebo 1102 5 3 3 4 9
ViP Rofecoxib 1099 6 2 1 3 8
A3191152 Naproxen 130 0 0 0 0 0
A3191152 Celecoxib 131 0 0 0 0 0
SUCCESS-1 (USA/Canada) Naproxen 165 1 2 0 0 3
SUCCESS-1 (USA/Canada) Celecoxib 353 4 2 1 1 4
ADVANTAGE Naproxen 526 1 6 0 4 7
ADVANTAGE Rofecoxib 528 5 1 4 5 10
VIGOR Naproxen 2008 4 9 7 15 17
VIGOR Rofecoxib 2007 20 11 9 22 34
TARGET (0117) Naproxen 4156 7 13 8 11 27
TARGET (0117) Lumiracoxib 4197 15 17 11 14 40
CLASS (N49-98-02-035) Ibuprofen 1123 9 6 6 8 17
CLASS (N49-98-02-035) Celecoxib 1184 9 2 6 9 13
TARGET (2332) Ibuprofen 3709 5 9 10 15 23
TARGET (2332) Lumiracoxib 3795 5 8 8 13 19
CAESAR Diclofenac 432 5 5 4 5 12
CAESAR Celecoxib 415 4 1 5 6 8
CLASS (N49-98-02-102) Diclofenac 1081 5 6 7 9 16
CLASS (N49-98-02-102) Celecoxib 1136 10 2 6 10 17
Emery 1999 Diclofenac 125 0 0 0 0 0
Emery 1999 Celecoxib 133 1 0 0 1 1
SUCCESS-1 (World) Diclofenac 745 0 4 4 5 4
SUCCESS-1 (World) Celecoxib 1472 6 6 1 4 12
EDGE Diclofenac 2607 11 6 4 8 12
EDGE Etoricoxib 2789 19 4 5 10 25
EDGE II Diclofenac 3251 25 12 7 18 42
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Antiplatelet Trialists’ Collaboration composite outcome
Thirty trialswith 1091 accumulated events contributed
to the analysis on the Antiplatelet Trialists’Collabora-
tion composite outcome (table 2). All drugs seemed to
be associated with increased risks of the composite of
non-fatal myocardial infarction, non-fatal stroke, or
cardiovascular death compared with placebo (fig 2).
The estimated rate ratios were greater than 1.3 for ibu-
profen (2.26, 1.11 to 4.89), diclofenac (1.60, 0.85 to
2.99), celecoxib (1.43, 0.94 to 2.16), etoricoxib (1.53,
0.74 to 3.17), rofecoxib (1.44, 1.00 to 1.99), and lumi-
racoxib (2.04, 1.13 to 4.24). Figure 3 presents an over-
view of pairwise comparisons (rate ratios with 95%
credibility intervals) of all drugs on all outcomes.
Posterior probabilities
Figure 4 presents posterior probability curves with
resulting confidence levels for the different drugs com-
pared with placebo and different outcomes. For exam-
ple, the probability that rofecoxib increases the risk of
myocardial infarction by less than 30% is 3% or con-
versely there is 97% confidence that rofecoxib
increases the risk by at least 30% (corresponding to a
rate ratio of 1.3). The curves can also be used to exam-
ine the overall pattern of available evidence of a speci-
fic drug. For example, the relatively steep increases in
all but one of the posterior probability curves for
naproxen points to the robust evidence available for
naproxen. In contrast, the relatively flat curves for etor-
icoxib indicate a relative lack of available evidence.
However, the mostly large effects seen for etoricoxib
(indicated by the right shift of the curves) nevertheless
allow conclusions for clinically relevant risk increases.
Evaluation of models, variation, and sensitivity analyses
Themodel fit was good for all outcomes (see web extra
appendix 2). Estimates of statistical heterogeneity
between direct comparisons were generally low,
except formyocardial infarction (rangeof τ2 across out-
comes: 0.03 to 0.12; see web extra appendix 2). Incon-
sistency between direct and indirect comparisons was
low for all outcomes (range of median inconsistency
factors 2% to 29%; see web extra appendix 2). How-
ever, given the relatively low number of trials and
events, relevant heterogeneity or inconsistency
between trials could not be ruled out. Detailed results
of the sensitivity analyses are presented in web extra
appendix 2: results were all compatible withmain ana-
lyses. Many of the estimates were imprecise, however,
and do not allow for firm conclusions to be drawn.
DISCUSSION
In this network meta-analysis of cardiovascular safety
data of seven non-steroidal anti-inflammatory drugs
and placebo, naproxen seemed least harmful (fig 3).
Safety profiles of individual drugs varied considerably
depending on the outcome, and estimated rate ratios
for comparisons with placebo were generally impre-
cise. Non-steroidal anti-inflammatory drugs are
mainly used for symptomatic treatment of musculo-
skeletal conditions. Clearly, as for any symptomatic
treatment, doing more harm than good with this class
of drugs should be avoided (primumnon nocere). Tak-
ing this into account, we presented confidence levels
(fig 4), which can be interpreted as confidence that a
drug is associatedwith an increase in risk that is smaller
than a specified threshold. For the primary outcome of
myocardial infarction, the confidence that the increase
in risk associatedwith the evaluated non-steroidal anti-
inflammatory drugs does not exceed 30% (the risk
increase used as non-inferiority margin in theMultina-
tional Etoricoxib and Diclofenac Arthritis Long-term
programme 16) is sufficiently high only for naproxen.
Conversely, we are confident that several other drugs
—ibuprofen, diclofenac, etoricoxib, and lumiracoxib
—are associated with a risk increase of more than
30% on several cardiovascular outcomes.
Although our analysis covered more than 100 000
patient years of follow-up, the number of events for
most outcomes was low and our estimates of rate ratios
imprecise, as indicated by wide credibility intervals.
Given the low event rates in the included trials,
Trial Intervention
Patient
years*
Myocardial
infarction† Stroke†
Cardiovascular
death Death‡
APTC composite
outcome
EDGE II Etoricoxib 3266 14 9 7 24 30
MEDAL Diclofenac 19 103 88 42 38 105 149
MEDAL Etoricoxib 19 970 84 48 39 95 154
Cannon 2000 Diclofenac 256 1 1 2 2 4
Cannon 2000 Rofecoxib 494 2 0 1 1 3
Saag 2000 Diclofenac 219 1 1 2 4 2
Saag 2000 Rofecoxib 443 2 1 0 0 3
Fleischmann 2003 Celecoxib 99 0 0 0 0 0
Fleischmann 2003 Lumiracoxib 207 2 0 0 0 2
Tannenbaum 2004 Celecoxib 110 0 0 0 0 NA
Tannenbaum 2004 Lumiracoxib 225 1 0 0 0 NA
Overall 117 218 554 377 312 676 1091
APTC=Antiplatelet Trialists’ Collaboration; NA=not available. See web extra appendix 3 for full names of trials.
*Slightly different numbers of patient years might be used for analysis of each outcome but only number of patient years for primary outcome
“incidence of myocardial infarction” is provided here.
†Includes fatal and non-fatal events.
‡Death from any cause.
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establishing the cardiovascular safety of a preparation
with sufficient precision would require a trial with
more than 100 000 patients followed up for at least
one year. Such a large trial may be difficult to carry
out, considering the limited amount of funding avail-
able and the inherent ethical problems. Although
estimated rate ratios indicated harmful effects in most
drugs on themajority of outcomes, conventional levels
of statistical significance were reached in about 30% of
comparisons with placebo. Absence of statistically
robust evidence of a harmful effect should not be con-
fused with evidence of absence of cardiovascular
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Fig 3 | Estimates of rate ratios for all possible comparisons of non-steroidal anti-inflammatory drugs. APTC=Antiplatelet Trialists’ Collaboration composite outcome
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 7 of 11
toxicity for the evaluated drugs.18 Posterior probabil-
ities may increase our understanding of cardiovascular
safety data in this situation and allow for different
notions about what constitutes a clinically relevant
increase in risk. Most will agree that a rate ratio of 1.3
indicates a clinically relevant increase in risk as was
used as the upper bound of the non-inferiority margin
by studies in the Multinational Etoricoxib and
Diclofenac Arthritis Long-term programme,16 and we
are confident that several drugs are associated with a
risk increase higher than this margin for several
outcomes.
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Fig 4 | Posterior probabilities for specified rate ratios. Curves can be used to extract a probability corresponding to a specified
minimally clinically relevant rate ratio or to extract a minimal rate ratio corresponding to a specified probability or confidence
level. For example, an increase in risk for myocardial infarction of at least 20% (rate ratio of at least 1.2) may be considered
clinically relevant. The curve for naproxen indicates that the probability of the drug being associated with a rate ratio below
this threshold is about 83%. Conversely, a probability of 90% may be considered as appropriate evidence for the outcome
stroke. The curve for celecoxib indicates that someone can be 90% confident that celecoxib increases the risk for stroke by no
more than 65% (rate ratio of 1.65). APTC=Antiplatelet Trialists’ Collaboration
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Some may argue that absolute rates of events were
low and clinically irrelevant, despite increases in rate
ratios. Event rates in the included trials are consider-
ably lower than in routine clinical settings.4 Numbers
needed to harm are therefore lower in routine settings
than inmost trial populations. The estimated rate ratios
observed in our study will translate into clinically
relevant numbers needed to harm in most routine
populations of patients taking non-steroidal anti-
inflammatory drugs, who are typically at moderate to
high risks for cardiovascular events.19
Strengths and weaknesses of the meta-analysis
Our analysis has several limitations. Firstly, we were
unable to consider all non-steroidal anti-inflammatory
drugs in our analysis: large scale randomised con-
trolled trials are lacking for most of the older drugs
and even for some newer ones, such as valdecoxib or
meloxicam. Nevertheless, we were able to include all
relevant cyclo-oxygenase-2 inhibitors, except valde-
coxib, and the three most commonly used traditional
non-steroidal anti-inflammatory drugs.20 21 By disre-
garding small studies we minimised the risk of small
study effects.22 Small studies would have had minimal
impact on the analysis anyway, because of low num-
bers of events.23 Secondly, we were able to obtain
unpublished data only for the trials of celecoxib and
lumiracoxib,whereasMerck, themanufacturer of rofe-
coxib and etoricoxib, was not willing to provide
unpublished safety data. Therefore some data were
missing for trials sponsored by Merck. This is discon-
certing in the light of the safety concerns raised by our
analysis for both drugs, rofecoxib and etoricoxib,man-
ufactured by Merck. Thirdly, the quality of our analy-
sis is limited by the quality of the underlying data.
Although the methodological quality of included trials
was generally satisfactory, the quality of reporting was
often less than optimal24 andwe found discrepancies in
the reported number of events between different
sources of information for major trials including
ADVANTAGE (Assessment of Differences between
Vioxx and Naproxen To Ascertain Gastrointestinal
Tolerability and Effectiveness), VIGOR (Vioxx
Gastrointestinal Outcomes Research), and APPROVe
(Adenomatous Polyp Prevention on Vioxx).3 25-27 Sev-
eral trials lacked independent adjudication of events,
therefore bias in either direction cannot be excluded,
including bias towards the null owing to non-differen-
tial misclassification of events or assessor bias in trials
without independent adjudication.423 Nevertheless,
the analysis restricted to trials with independent adju-
dication of events supported the robustness of our
main analysis (see web extra appendix 2). Fourthly,
one study explored the effects of dosage and regimen
in a pooled analysis of six randomised placebo
controlled trials of celecoxib and found that lower
dosages and once daily regimens that avoided contin-
uous interference of the drug with prostaglandin meta-
bolismwere associated with lower relative risks for the
cardiovascular composite outcome than higher
dosages and twice daily regimens.28 We were unable
to satisfactorily deal with these matters in our analysis
mainly because of the complexity of the network and
the lownumber of patients treatedwith lowdosages. In
addition, regimens used in clinical practicemight differ
from the regimens used in the included clinical trials.
Intermittent usage seems to be more common in clin-
ical practice than the chronic long term usage in the
trials, resulting in less intense drug use.29 Because
none of the trials used intermittent regimens and
drugswere used for at least one year inmost of the trials
wewere unable to investigate the impact of drug use on
cardiovascular outcomes. Data from the General Prac-
tice Research Database indicate, however, that about
half of the patients have patterns of drug intake com-
parable to those evaluated in the trials included in this
networkmeta-analysis,29 andwe submit that the results
of our study are applicable to these patients. Finally,we
carried out several sensitivity analyses to determine the
robustness of the results. Unfortunately, owing to the
low number of accumulated events, estimates from
these analyses were imprecise and do not allow any
meaningful conclusion. This is particularly true for
the analysis restricted to patients with musculoskeletal
conditions: many of the point estimates could not be
derived at all and others seemed to contradict themain
results, but credibility intervals were compatible with
both, major benefits or detrimental harms.
We used a comprehensive search strategy and
searched pertinent sources to retrieve potentially eligi-
ble randomised controlled trials.30 It therefore seems
unlikely that we missed any relevant trial. Using net-
work meta-analysis we were able to integrate all avail-
able randomised evidence on the cardiovascular safety
of non-steroidal anti-inflammatory drugs in one analy-
sis while fully preserving randomisation.31 The integra-
tion of direct and indirect comparisons results in a gain
of statistical precision compared with previous
analyses4 23 and allows for formal comparisons of
non-steroidal anti-inflammatory drugs with placebo.
In the most comprehensive analysis to date, one
study compared five cyclo-oxygenase-2 selective inhi-
bitors with placebo using conventional techniques.23
They found all estimates of relative risks of cardio-
vascular death imprecise and largely overlapping the
null effect line, compatible with substantial harms or
benefits. In contrast, our estimates were more precise
compared with that study, which estimated a nearly
identical rate ratio for the comparison of etoricoxib
and placebo for the outcome cardiovascular death
(rate ratio 4.4 v 4.07 in our analysis). However, the con-
fidence interval in that meta-analysis ranged from 0.2
to 119 whereas our credibility interval ranged from
1.23 to 15.7, providing stronger evidence for increases
in the risk of cardiovascular death. Also, wide confi-
dence intervals around estimates for lumiracoxib did
not allow for a conclusion on any of the outcomes in
their analysis. In contrast, our analysis provided smal-
ler intervals, and posterior probabilities indicated a
high probability that lumiracoxib is associated with a
clinically relevant increase in risk of cardiovascular
outcomes.
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Comparison with other studies
Our study confirms previous notions of regulatory
bodies, mainly based on observational evidence, that
all non-steroidal anti-inflammatory drugs are asso-
ciated with an increased risk of cardiovascular adverse
effects.32 33 Observational evidence is likely to be
affected by confounding by indication.34 Our results
are based on randomised evidence and we therefore
believe that our study provides the best available evi-
dence on the safety of this class of drugs. Nevertheless,
our results are mostly compatible with the results of a
meta-analysis of observational studies—for example,
for naproxen, diclofenac, or rofecoxib—although
some differences exist, especially for ibuprofen.5
Besides confounding by indication, these differences
might be explained not only by differences in drug
use between trials and observational studies29 but also
by the quality of observational studies, which lead to
high heterogeneity between studies and a possible
underestimation of effects.5 35
We found no clear relation between specificity of
cyclo-oxygenase-2 inhibitors and risk of cardio-
vascular events. This finding contrasts with previous
claims that increased selectivity for cyclo-oxygenase-
2 inhibitors is associatedwith increased cardiovascular
risk.36 Several mechanisms have been postulated, but
the hypothesis of an imbalance between prostacyclin
and thromboxane A2 leading to an increased risk for
thombotic events gained most prominence.37 How-
ever, the lack of a clear association between specificity
of cyclo-oxygenase-2 inhibitors and cardiovascular
risk implies that other mechanisms need to be consid-
ered. Multiple effects most probably contribute to the
increased risk of cardiovascular events, including dif-
ferential effects on prostacyclin and thromboxane A2
synthesis,37 endothelial function and nitric oxide
production,38 blood pressure,39 volume retention and
other renal effects.40 In addition, differences in phar-
macokinetics may contribute to the toxicity profile41;
drugswith a longhalf life prescribedoncedaily (such as
rofecoxib) and drugs with a shorter half life prescribed
more than once daily (such as diclofenac)may bemore
likely to continuously interfere with the cyclo-
oxygenase system than drugs with a shorter half life
prescribed once daily (such as celecoxib).28
Implications and conclusions
The observation that cardiovascular risk is not clearly
associatedwith specificity of cyclo-oxygenase-2 inhibi-
tors implies that no prediction of cardiovascular risk
can be made based on such specificity. Therefore the
use of other non-steroidal anti-inflammatory drugs not
covered by our analysis should be reconsidered, as
well as the over the counter availability of non-steroi-
dal anti-inflammatory drugs such as diclofenac or ibu-
profen. In general, naproxen seems to be the safest
analgesic for patients with osteoarthritis in cardio-
vascular terms but this advantage has to be weighed
against gastrointestinal toxicity and the need for con-
comitant prescription of a proton pump inhibitor in
many patients. In the light of the results of one
study,28 celecoxib 400 mg prescribed once daily may
be considered as an alternative option. Other alterna-
tives include paracetamol and opioids.Comparedwith
placebo, however, paracetamol results in only a small
reduction in pain andmay be associated with clinically
relevant hepatotoxicity, even in dosages recom-
mended for musculoskeletal pain.42 43 The analgesic
effect of opioids is somewhat more pronounced but
outweighed by large increases in the risk of adverse
events.44 In conclusion, the options for the treatment
of chronic musculoskeletal pain are limited and
patients and clinicians need to be aware that cardio-
vascular risk needs to be taken into account when pre-
scribing.
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